Cargando…

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation

BACKGROUND: Airway microbiota composition has been clearly correlated with many pulmonary diseases, and notably with cystic fibrosis (CF), an autosomal genetic disorder caused by mutation in the CF transmembrane conductance regulator (CFTR). Recently, a new molecule, ivacaftor, has been shown to re-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernarde, Cédric, Keravec, Marlène, Mounier, Jérôme, Gouriou, Stéphanie, Rault, Gilles, Férec, Claude, Barbier, Georges, Héry-Arnaud, Geneviève
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390299/ https://www.ncbi.nlm.nih.gov/pubmed/25853698 http://dx.doi.org/10.1371/journal.pone.0124124

Ejemplares similares

Porphyromonas, a potential predictive biomarker of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis
por: Keravec, Marlène, et al.
Publicado: (2019)

Insights into the respiratory tract microbiota of patients with cystic fibrosis during early Pseudomonas aeruginosa colonization
por: Keravec, Marlène, et al.
Publicado: (2015)

A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014)

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
por: Quittner, Alexandra, et al.
Publicado: (2015)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation
por: Wood, Michelle E, et al.
Publicado: (2013)

Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
por: Zeybel, Gemma L., et al.
Publicado: (2017)

Proteomic Identification of Calumenin as a G551D - CFTR Associated Protein
por: Teng, Ling, et al.
Publicado: (2012)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis
por: Le Gall, Florence, et al.
Publicado: (2013)

A small molecule CFTR potentiator restores ATP‐dependent channel gating to the cystic fibrosis mutant G551D‐CFTR
por: Liu, Jia, et al.
Publicado: (2022)

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiators Protect G551D but Not ΔF508 CFTR from Thermal Instability
por: Liu, Xuehong, et al.
Publicado: (2014)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization
por: Enaud, Raphael, et al.
Publicado: (2023)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
por: Bell, Scott C., et al.
Publicado: (2019)

Prevotella melaninogenica, a Sentinel Species of Antibiotic Resistance in Cystic Fibrosis Respiratory Niche?
por: Lamoureux, Claudie, et al.
Publicado: (2021)

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
por: Gelfond, Daniel, et al.
Publicado: (2017)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor
por: Mainz, Jochen G., et al.
Publicado: (2021)

The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery
por: Scotet, Virginie, et al.
Publicado: (2020)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018)

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor
por: Barbieri, Alessandro, et al.
Publicado: (2021)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
por: Sommerburg, Olaf, et al.
Publicado: (2021)

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid
por: Mainz, Jochen G., et al.
Publicado: (2021)

Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)
por: Lingam, Swathi, et al.
Publicado: (2017)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

The Microbiome in Cystic Fibrosis Pulmonary Disease
por: Françoise, Alice, et al.
Publicado: (2020)

Potentiation of ΔF508- and G551D-CFTR-Mediated Cl(-) Current by Novel Hydroxypyrazolines
por: Park, Jinhong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hr5dufrmv0bm4eee3t1of0tu4j